Covid19 Vaccine

Infectious Diseases
8
Pipeline Programs
2
Companies
8
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
6
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Medigen Vaccine Biologics
6 programs
5
1
MVC-COV1901Phase 31 trial
MVC-COV1901Phase 21 trial
MVC-COV1901Phase 21 trial
MVC-COV1901Phase 21 trial
MVC-COV1901Phase 21 trial
+1 more programs
Active Trials
NCT04951388CompletedEst. Mar 2022
NCT04695652CompletedEst. Oct 2021
NCT05038618CompletedEst. Mar 2022
+3 more trials
Providence Therapeutics
2 programs
1
1
PTX-COVID19-BPhase 21 trial
PTX-COVID19-BPhase 11 trial
Active Trials
NCT04765436CompletedEst. Mar 2022
NCT05175742CompletedEst. Mar 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Medigen Vaccine BiologicsMVC-COV1901
Providence TherapeuticsPTX-COVID19-B
Medigen Vaccine BiologicsMVC-COV1901
Medigen Vaccine BiologicsMVC-COV1901
Medigen Vaccine BiologicsMVC-COV1901
Medigen Vaccine BiologicsMVC-COV1901
Medigen Vaccine BiologicsMVC-COV1901
Providence TherapeuticsPTX-COVID19-B

Clinical Trials (8)

A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 Against COVID-19 in Adults

Start: Oct 2021Est. completion: May 2022
Phase 3Completed

PTX-COVID19-B, an mRNA Humoral Vaccine, Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Demonstrate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B in Comparison to the Pfizer-BioNTech COVID-19 Vaccine.

Start: Aug 2021Est. completion: Mar 2023
Phase 2Completed

A Study o Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901, CT-COV-21 Sub-study

Start: Aug 2021Est. completion: Mar 2022
Phase 2Completed

A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adolescents

Start: Jul 2021Est. completion: Mar 2022
Phase 2Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of COVID-19 Vaccine, CT-COV-21 Extension Study

Start: Jul 2021Est. completion: Apr 2022
Phase 2Completed

A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Elderly Adults

Start: May 2021Est. completion: Jan 2022
Phase 2Completed

A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adult

Start: Dec 2020Est. completion: Oct 2021
Phase 2Completed

PTX-COVID19-B, an mRNA Humoral Vaccine, is Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Evaluate Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Vaccine in Healthy Seronegative Adults Aged 18-64

Start: Jan 2021Est. completion: Mar 2022
Phase 1Completed

Related Jobs in Infectious Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space